NZ575093A - Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma - Google Patents

Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Info

Publication number
NZ575093A
NZ575093A NZ575093A NZ57509307A NZ575093A NZ 575093 A NZ575093 A NZ 575093A NZ 575093 A NZ575093 A NZ 575093A NZ 57509307 A NZ57509307 A NZ 57509307A NZ 575093 A NZ575093 A NZ 575093A
Authority
NZ
New Zealand
Prior art keywords
antibody
fragment
seq
afra
heavy chain
Prior art date
Application number
NZ575093A
Other languages
English (en)
Inventor
Franck Martin
Margherita Cattozzo
Giovanni Maurizi
Cioccio Vito Di
Mariangela Figini
Silvana Canevari
Original Assignee
Dompe Pha R Ma Spa Res & Mfg
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Pha R Ma Spa Res & Mfg, Ist Naz Stud Cura Dei Tumori filed Critical Dompe Pha R Ma Spa Res & Mfg
Publication of NZ575093A publication Critical patent/NZ575093A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ575093A 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma NZ575093A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06019399A EP1900752A1 (en) 2006-09-15 2006-09-15 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
PCT/EP2007/007944 WO2008031577A1 (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Publications (1)

Publication Number Publication Date
NZ575093A true NZ575093A (en) 2012-04-27

Family

ID=37737768

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ575093A NZ575093A (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Country Status (14)

Country Link
US (1) US8388972B2 (cg-RX-API-DMAC7.html)
EP (2) EP1900752A1 (cg-RX-API-DMAC7.html)
JP (1) JP5513114B2 (cg-RX-API-DMAC7.html)
KR (1) KR101497045B1 (cg-RX-API-DMAC7.html)
AU (1) AU2007296899B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716811B8 (cg-RX-API-DMAC7.html)
CA (1) CA2662005C (cg-RX-API-DMAC7.html)
ES (1) ES2644423T3 (cg-RX-API-DMAC7.html)
IL (1) IL197300A (cg-RX-API-DMAC7.html)
MX (1) MX2009002711A (cg-RX-API-DMAC7.html)
NZ (1) NZ575093A (cg-RX-API-DMAC7.html)
RU (1) RU2464277C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008031577A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901328B (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
EP3401333B1 (en) 2010-09-09 2021-05-19 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
RU2630608C2 (ru) * 2010-11-05 2017-09-11 Морфотек Инк. Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2687231A4 (en) 2011-03-18 2014-10-22 Univ Kagoshima COMPOSITION FOR THE TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER
CA2831426C (en) * 2011-04-01 2023-02-21 Immunogen, Inc. Methods for increasing efficacy of folr1 cancer therapy
PL2731972T3 (pl) 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania
MX356947B (es) 2011-08-23 2018-06-20 Roche Glycart Ag Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
CN104755498B (zh) * 2012-08-31 2019-06-18 伊缪诺金公司 用于检测叶酸受体1的诊断测定和试剂盒
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
US9637547B2 (en) * 2013-08-30 2017-05-02 Immunogen, Inc. Monoclonal antibodies for detection of folate receptor 1
SG10202102555TA (en) * 2013-10-08 2021-04-29 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
HRP20201928T1 (hr) 2014-11-20 2021-02-05 F. Hoffmann - La Roche Ag Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
MX2017006571A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Moleculas de union a antigeno biespecificas activadoras de celulas t.
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
WO2018031980A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
CA3177187A1 (en) 2016-08-12 2018-02-15 L.E.A.F Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2019094648A1 (en) 2017-11-08 2019-05-16 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
MX2020009522A (es) 2018-03-13 2020-10-22 Phanes Therapeutics Inc Anticuerpos anti-folato del receptor 1 y usos de los mismos.
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
CA3138272A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
EP4010031A1 (en) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Processes of preparing polyglutamated antifolates and uses of their compositions
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段
CN119757601A (zh) * 2025-01-06 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于卵巢癌诊断的代谢标志物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20050232919A1 (en) * 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP1945772B1 (en) * 2005-10-06 2015-11-18 Advanced Accelerator Applications S.A. Novel selection system

Also Published As

Publication number Publication date
JP5513114B2 (ja) 2014-06-04
ZA200901328B (en) 2010-05-26
RU2009114161A (ru) 2010-10-20
EP2061813B1 (en) 2017-07-19
BRPI0716811B1 (pt) 2020-11-24
EP1900752A1 (en) 2008-03-19
KR101497045B1 (ko) 2015-02-27
RU2464277C2 (ru) 2012-10-20
MX2009002711A (es) 2009-06-18
WO2008031577A8 (en) 2009-07-02
BRPI0716811A2 (pt) 2013-11-05
BRPI0716811B8 (pt) 2021-05-25
US8388972B2 (en) 2013-03-05
KR20090059114A (ko) 2009-06-10
AU2007296899B2 (en) 2012-09-13
US20100055034A1 (en) 2010-03-04
WO2008031577A1 (en) 2008-03-20
ES2644423T3 (es) 2017-11-28
IL197300A (en) 2016-02-29
AU2007296899A1 (en) 2008-03-20
IL197300A0 (en) 2011-08-01
JP2010503386A (ja) 2010-02-04
EP2061813A1 (en) 2009-05-27
CA2662005C (en) 2018-01-02
CA2662005A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
AU2007296899B2 (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP6077745B2 (ja) 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物
AU2017288985B2 (en) Anti-MET antibodies and uses thereof
CN106188305A (zh) 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
WO2022166876A1 (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
CA3203257A1 (en) Anti-b7-h3 antibody and uses thereof
JP2024537321A (ja) ヒトおよびカニクイザルタンパク質に対して交差反応性を有する抗ｃｄ３抗体
KR20250042144A (ko) Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same)
US20240417469A1 (en) Cd3-targeting t-cell engagers with improved therapeutic index
JP2025520692A (ja) 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用
US10584175B2 (en) FN14-binding proteins and uses thereof
US20240026004A1 (en) ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025195495A1 (zh) 一种放射性核素偶联物及其制备方法和用途
KR20250174736A (ko) L1cam을 표적화하는 항체 및 이의 용도
KR20250069411A (ko) 항 ceacam5 항체 및 이의 용도
TW202539735A (zh) 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物
CN120025446A (zh) 结合分子及抗体药物偶联物和用途
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
CA2962902C (en) Binding molecules, especially antibodies, binding to l1cam (cd171)
CN117402255A (zh) 抗人pd-l1和人ox40的双特异抗体及其应用
BR112018005837B1 (pt) Anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 SEP 2017 BY CPA GLOBAL

Effective date: 20140731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2018 BY CPA GLOBAL

Effective date: 20170727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2019 BY ACUMASS

Effective date: 20180817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2020 BY ACUMASS

Effective date: 20190819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2021 BY ACUMASS

Effective date: 20200819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2022 BY ACUMASS

Effective date: 20210823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2023 BY OLIVIER BARLOY

Effective date: 20220811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2024 BY CPA GLOBAL

Effective date: 20230817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250821